+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Desvenlafaxine"

Antidepressants Global Market Report 2024 - Product Thumbnail Image

Antidepressants Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026 - Product Thumbnail Image

US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026

  • Report
  • February 2021
  • 420 Pages
  • United States
From
Pristiq (desvenlafaxine; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Pristiq (desvenlafaxine; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 17 Pages
  • Global
Fetzima (levomilnacipran; Allergan) Drug Overview 2019 - Product Thumbnail Image

Fetzima (levomilnacipran; Allergan) Drug Overview 2019

  • Report
  • March 2019
  • 17 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD). It is a synthetic form of the active metabolite of venlafaxine, an antidepressant. Desvenlafaxine is used to treat depression, anxiety, and other mental health disorders. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps to improve mood and reduce symptoms of depression. Desvenlafaxine is available in both immediate-release and extended-release formulations. The extended-release formulation is used to treat depression in adults. Desvenlafaxine is a relatively new drug in the mental disorders drugs market. It is generally well-tolerated and has fewer side effects than other antidepressants. It is also effective in treating depression in patients who have not responded to other antidepressants. Some companies in the desvenlafaxine market include Pfizer, Mylan, and Sun Pharmaceuticals. Show Less Read more